Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lumiracoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.56 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.56 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.56 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lumiracoxib SCHEMBL29475008 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL29377334 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL27680523 | 0.99 | PTGS2 (0.98) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL6063194 | 0.93 | PTGS2 (0.87) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL1031733 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL17917294 | 0.91 | PTGS2 (0.85) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL5533958 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL3120262 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL17208147 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL5534966 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11NR1I3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22489 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| US-20260069532-A1 | METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE | MEDINCELL S.A. (FR) | 2026-03-12 | — | — | US | claimed |
| US-20260061062-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | UNIV NEBRASKA (US) | 2026-03-05 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-12558309-B2 | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue | MEDINCELL S.A. (FR) | 2026-02-24 | — | — | US | claimed |
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | PARKER DANE K (US) | 2026-02-10 | — | — | US | claimed |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | claimed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| WO-2002078626-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | PHARMACIA CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-6451858-B2 | FOR THERAPY OF INFLAMMATION, PYRESIS, PAIN, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, MIGRAINE HEADACHE, CANCER, MELANOMA, MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, OSTEOPOROSIS, ASTHMA, LUPUS AND PSORIASIS; SIDE EFFECT REDUCTION | NOVARTIS AG (CH) | 2002-09-17 | — | — | US | claimed |
| EP-1216226-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | Novartis AG (CH) | 2002-06-26 | — | — | EP | claimed |
| US-20020061932-A1 | Pharmaceutical composition | GIMONA ALBERTO (CH) | 2002-05-23 | — | — | US | claimed |
| WO-2002020090-A2 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2002-03-14 | — | — | WO | claimed |
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-01-31 | — | — | US | claimed |
| US-6310099-B1 | 5-METHYL OR ETHYL-2-(2-'CHLORO OR FLUORO OR TRIFLUROMETHYL-6'FLUORO OR CHLOROANILINO) PHENYLACETIC ACID OR SALT IS USED AS COX-2 SELECTIVE CYCLOOXYGENASE INHIBITOR | NOVARTIS AG (CH) | 2001-10-30 | — | — | US | claimed |
| US-6291523-B1 | SELECTIVE COX-2 CYCLOOXYGENASE INHIBITORS | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | claimed |
| WO-2001023346-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-04-05 | — | — | WO | claimed |